Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Congress 2022 | Are megakaryocytes the root of MPN evils?

Joseph Scandura • 24 Nov 2022
MPN Congress 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Joseph Scandura, MD, PhD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, gives a presentation on the role of megakaryocytes in myeloproliferative neoplasms (MPNs) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Joseph Scandura

The risk and management of pulmonary hypertension in patients with polycythemia vera 4:27
The risk and management of pulmonary hypertension in patients with polycythemia vera
Joseph Scandura • 23 Aug 2025
Neutrophil-to-lymphocyte ratio: a potential dynamic biomarker of treatment response in PV 3:20
Neutrophil-to-lymphocyte ratio: a potential dynamic biomarker of treatment response in PV
Joseph Scandura • 23 Aug 2025
Satiety inhibition in MPNs: the effect of JAKi treatment on leptin levels and body weight 2:26
Satiety inhibition in MPNs: the effect of JAKi treatment on leptin levels and body weight
Joseph Scandura • 23 Aug 2025
Translational aspects of MPNs: investigating disease biology 1:36
Translational aspects of MPNs: investigating disease biology
Joseph Scandura • 24 Aug 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals